One recently published study suggests that a cannabis sublingual spray may be beneficial in the treatment of type 2 diabetes.
Published in the Iranian Journal of Pharmaceutical Research, the phase I randomized, double-blind, placebo-controlled study aimed to evaluate the safety profile and efficacy of a cannabis-based sublingual spray, CBDEX10 (containing 100 µg cannabidiol and 10 µg Δ9-tetrahydrocannabinol per puff; CBD/Δ9-THC 10:1) (1).
The study tracked 50 diabetic patients over an eight-week treatment period to assess the efficacy of the twice daily administered supplementary therapy in controlling the glycemic state and lipid profile of the patients (1). It noted prior research on cannabis use and insulin levels and body mass index in the rationale behind using a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in conjunction with the main anti-diabetic medication (1).
“In the present study, we demonstrated that sublingual administration of the CBDEX1 sublingual spray, two puffs twice daily through an eight-week treatment period, could effectively improve the patient's lipid profile and glucose tolerance. Moreover, the mentioned regimen could also improve insulin sensitivity,” the study concluded, noting a statistically significant decline in total cholesterol in the supplement group by the end of the study (1). “Overall, CBDEX1 sublingual spray could be a new therapeutic agent for lipid and glycemic control in diabetic patients.”
There were no statistically significant differences regarding demographics or adverse effects between the supplement and placebo groups (1).